BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 23324805)

  • 1. FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder.
    Ellsworth KA; Moon I; Eckloff BW; Fridley BL; Jenkins GD; Batzler A; Biernacka JM; Abo R; Brisbin A; Ji Y; Hebbring S; Wieben ED; Mrazek DA; Weinshilboum RM; Wang L
    Pharmacogenet Genomics; 2013 Mar; 23(3):156-66. PubMed ID: 23324805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of FKBP5 genetic variation to gemcitabine treatment and survival in pancreatic adenocarcinoma.
    Ellsworth KA; Eckloff BW; Li L; Moon I; Fridley BL; Jenkins GD; Carlson E; Brisbin A; Abo R; Bamlet W; Petersen G; Wieben ED; Wang L
    PLoS One; 2013; 8(8):e70216. PubMed ID: 23936393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Catechol O-methyltransferase pharmacogenomics and selective serotonin reuptake inhibitor response.
    Ji Y; Biernacka J; Snyder K; Drews M; Pelleymounter LL; Colby C; Wang L; Mrazek DA; Weinshilboum RM
    Pharmacogenomics J; 2012 Feb; 12(1):78-85. PubMed ID: 20877297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of association of FKBP5 SNPs and haplotypes with susceptibility and treatment response phenotypes in Han Chinese with major depressive disorder: A pilot case-control study (STROBE).
    Yang C; Li S; Ma Y; Chen B; Li M; Bosker FJ; Li J; Nolte IM
    Medicine (Baltimore); 2021 Sep; 100(36):e26983. PubMed ID: 34516490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of FKBP5 polymorphisms with suicidal events in the Treatment of Resistant Depression in Adolescents (TORDIA) study.
    Brent D; Melhem N; Ferrell R; Emslie G; Wagner KD; Ryan N; Vitiello B; Birmaher B; Mayes T; Zelazny J; Onorato M; Devlin B; Clarke G; DeBar L; Keller M
    Am J Psychiatry; 2010 Feb; 167(2):190-7. PubMed ID: 20008943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment.
    Horstmann S; Lucae S; Menke A; Hennings JM; Ising M; Roeske D; Müller-Myhsok B; Holsboer F; Binder EB
    Neuropsychopharmacology; 2010 Feb; 35(3):727-40. PubMed ID: 19924111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The FKBP5-gene in depression and treatment response--an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort.
    Lekman M; Laje G; Charney D; Rush AJ; Wilson AF; Sorant AJ; Lipsky R; Wisniewski SR; Manji H; McMahon FJ; Paddock S
    Biol Psychiatry; 2008 Jun; 63(12):1103-10. PubMed ID: 18191112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Female sexual dysfunction in patients with major depressive disorder (MDD) treated with selective serotonin reuptake inhibitor (SSRI) and its association with serotonin 2A-1438 G/A single nucleotide polymorphisms.
    Masiran R; Sidi H; Mohamed Z; Mohd Nazree NE; Nik Jaafar NR; Midin M; Das S; Mohamed Saini S
    J Sex Med; 2014 Apr; 11(4):1047-1055. PubMed ID: 24533444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics.
    Ji Y; Biernacka JM; Hebbring S; Chai Y; Jenkins GD; Batzler A; Snyder KA; Drews MS; Desta Z; Flockhart D; Mushiroda T; Kubo M; Nakamura Y; Kamatani N; Schaid D; Weinshilboum RM; Mrazek DA
    Pharmacogenomics J; 2013 Oct; 13(5):456-63. PubMed ID: 22907730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response.
    Biernacka JM; Sangkuhl K; Jenkins G; Whaley RM; Barman P; Batzler A; Altman RB; Arolt V; Brockmöller J; Chen CH; Domschke K; Hall-Flavin DK; Hong CJ; Illi A; Ji Y; Kampman O; Kinoshita T; Leinonen E; Liou YJ; Mushiroda T; Nonen S; Skime MK; Wang L; Baune BT; Kato M; Liu YL; Praphanphoj V; Stingl JC; Tsai SJ; Kubo M; Klein TE; Weinshilboum R
    Transl Psychiatry; 2015 Apr; 5(4):e553. PubMed ID: 25897834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenomics-Driven Prediction of Antidepressant Treatment Outcomes: A Machine-Learning Approach With Multi-trial Replication.
    Athreya AP; Neavin D; Carrillo-Roa T; Skime M; Biernacka J; Frye MA; Rush AJ; Wang L; Binder EB; Iyer RK; Weinshilboum RM; Bobo WV
    Clin Pharmacol Ther; 2019 Oct; 106(4):855-865. PubMed ID: 31012492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pleiotropic genes in psychiatry: Calcium channels and the stress-related FKBP5 gene in antidepressant resistance.
    Fabbri C; Corponi F; Albani D; Raimondi I; Forloni G; Schruers K; Kasper S; Kautzky A; Zohar J; Souery D; Montgomery S; Cristalli CP; Mantovani V; Mendlewicz J; Serretti A
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Feb; 81():203-210. PubMed ID: 28989100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics studies in STAR*D: strengths, limitations, and results.
    Laje G; Perlis RH; Rush AJ; McMahon FJ
    Psychiatr Serv; 2009 Nov; 60(11):1446-57. PubMed ID: 19880459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FKBP5 polymorphisms and hypothalamic-pituitary-adrenal axis negative feedback in major depression and obsessive-compulsive disorder.
    Ferrer A; Costas J; Labad J; Salvat-Pujol N; Segalàs C; Urretavizcaya M; Real E; de Arriba-Arnau A; Alonso P; Crespo JM; Barrachina M; Soriano-Mas C; Carracedo Á; Menchón JM; Soria V
    J Psychiatr Res; 2018 Sep; 104():227-234. PubMed ID: 30107269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SLC6A4 variation and citalopram response.
    Mrazek DA; Rush AJ; Biernacka JM; O'Kane DJ; Cunningham JM; Wieben ED; Schaid DJ; Drews MS; Courson VL; Snyder KA; Black JL; Weinshilboum RM
    Am J Med Genet B Neuropsychiatr Genet; 2009 Apr; 150B(3):341-51. PubMed ID: 18618621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample.
    Kraft JB; Peters EJ; Slager SL; Jenkins GD; Reinalda MS; McGrath PJ; Hamilton SP
    Biol Psychiatry; 2007 Mar; 61(6):734-42. PubMed ID: 17123473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics.
    Gupta M; Neavin D; Liu D; Biernacka J; Hall-Flavin D; Bobo WV; Frye MA; Skime M; Jenkins GD; Batzler A; Kalari K; Matson W; Bhasin SS; Zhu H; Mushiroda T; Nakamura Y; Kubo M; Wang L; Kaddurah-Daouk R; Weinshilboum RM
    Mol Psychiatry; 2016 Dec; 21(12):1717-1725. PubMed ID: 26903268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age-associated epigenetic upregulation of the FKBP5 gene selectively impairs stress resiliency.
    Sabbagh JJ; O'Leary JC; Blair LJ; Klengel T; Nordhues BA; Fontaine SN; Binder EB; Dickey CA
    PLoS One; 2014; 9(9):e107241. PubMed ID: 25191701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Common genetic variation in the indoleamine-2,3-dioxygenase genes and antidepressant treatment outcome in major depressive disorder.
    Cutler JA; Rush AJ; McMahon FJ; Laje G
    J Psychopharmacol; 2012 Mar; 26(3):360-7. PubMed ID: 22282879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A functional variant in the serotonin receptor 7 gene (HTR7), rs7905446, is associated with good response to SSRIs in bipolar and unipolar depression.
    Wei YB; McCarthy M; Ren H; Carrillo-Roa T; Shekhtman T; DeModena A; Liu JJ; Leckband SG; Mors O; Rietschel M; Henigsberg N; Cattaneo A; Binder EB; Aitchison KJ; Kelsoe JR
    Mol Psychiatry; 2020 Jun; 25(6):1312-1322. PubMed ID: 30874608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.